Boothbay Fund Management, LLC Altimmune, Inc. Call Options Transaction History

Boothbay Fund Management, LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2024 Feb 14, 2025	BUY	$6.02 - $9.85 $287,756 - $470,830	47,800 New	47,800 $344,000
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $452,939 - $1.82 Million	108,100 Added 95.33%	221,500 $934,000
Q4 2022 Feb 14, 2023	SELL	$8.74 - $16.45 $1.21 Million - $2.28 Million	-138,800 Reduced 55.04%	113,400 $1.87 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $2.26 Million - $4.74 Million	211,600 Added 521.18%	252,200 $3.22 Million
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $159,964 - $477,862	40,600 New	40,600 $475,000

209

39.5M

1.94M

1.38M

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $325M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.